[Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].

Abstract

Pancreatic ductal carcinoma is a highly aggressive cancer, with one of the highest mortality rates among gastrointestinal cancers. Nab-paclitaxel plus gemcitabine (GEM) significantly improved overall survival, progression-free survival, and response rate in a phase Ⅲ trial in 151 community and academic centers in 11 countries. As a result, nab-paclitaxel plus GEM was approved for use in December 2014 in Japan. We report a case of a patient with pancreatic cancer who underwent this chemotherapy. A 47-year-old man was admitted to our hospital for evaluation of pancreatic lesions. Computed tomography revealed a hypoattenuating tumor in the body of the pancreas. After the patient underwent preoperative chemoradiotherapy under the diagnosis of cStage Ⅳa cancer, we planned to perform distal pancreatectomy. However, this case was inoperable because we found 3 liver metastases during surgery. On postoperative day 14, we treated the patient with nab-paclitaxel plus GEM. Grade 2 toxicities included neutropenia, diarrhea, and peripheral neuropathy, but serious adverse events did not occur. The progression-free survival was 5 months. He remained alive for 7 months after the chemotherapy. In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus GEM can be considered as the standard treatment.

• Authors: Yoshiteru Katsura, Yutaka Takeda, Yoshiaki Ohmura, Yurina Motoyama, Tomo Ishida, Yoshihiro Morimoto, Katsunori Matsushita, Atsushi Naito, Kohei Murakami, Yoshinori Kagawa, Masatsugu Okishiro, Atsushi Takeno, Chiyomi Egawa, Takeshi Kato, Shigeyuki Tamura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 12 Pg. 2367-9 (Nov 2015) ISSN: 0385-0684 [Print] Japan
• PMID: 26805366 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• 130-nm albumin-bound paclitaxel
• Albumins
• Deoxycytidine
• Paclitaxel
• Gemcitabine

Topics

• Albumins (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Humans
• Liver Neoplasms (drug therapy, secondary)
• Male
• Middle Aged
• Paclitaxel (administration & dosage)
• Pancreatic Neoplasms (drug therapy, pathology)
• Treatment Outcome
• Gemcitabine